

厚生労働行政推進調査事業費補助金（肝炎等克服政策研究事業）
分担研究報告書

肝がん・重度肝硬変の治療に係るガイドラインの作成等に資する研究

工藤 正俊 近畿大学医学部 消化器内科 主任教授

研究要旨

データ収集プラットフォーム整備

A. 研究目的

1. 肝癌重度肝硬変のうち特に肝癌の治療に係る各国の研究状況と診療の実態調査。
2. 肝癌に対する新しい免疫療法薬の効果と安全性を検証し論文報告を行う。

B. 研究方法

1. 肝癌に関する各種国際学会に Web 出席し、各国における各ステージにおける治療成績、治療の適応などにおいて我が国と比較を行った。
2. 新しい薬剤に関する効果と安全性を検証し論文発表を行った。

C. 研究結果

日本の肝癌のサーベイランス、診断、治療は他国と比べて優れているということ、および治療方針なども他国と大きく異なっていることが明らかとなった。

また、免疫療法などは効果があり治癒に持ち込めるケースもあることが判明した。

D. 考察

今後日本において肝癌や重度肝硬変において効率的に進めるためには、患者の経済的サポートも重要と考えられた。

E. 結論

日本の肝癌の診療レベルは世界的に優れているが、更に患者の経済的援助が必要と考えられた。

F. 健康危険情報

なし

G. 研究発表

1) 論文発表

1. Kudo M, Morimoto M, Moriguchi M, Izumi N, Takayama T, Yoshiji H, Hino K, Oikawa T, Chiba T, Motomura K, Kato J, Yasuchika K, Ido A, Sato T, Ikawa Y, Ueshima K, Ikeda M, Okusaka T, Tamura K, Furuse J: A randomized, double-blind, placebo-controlled, phase III study of tivantinib in Japanese patients with MET-high hepatocellular carcinoma. *Cancer Sci* 2021;111:3759-3769.
2. Hughes DM, Berhane S, de Groot CAE, Toyoda H, Tada T, Kumada T, Satomura S, Nishida N, Kudo M, Kimura T, Osaki Y, Kolamunage-Dona R, Salvador RA, Bird T, Garcia-Finana M, Johnson P: Serum levels of alpha fetoprotein increased more than 10 years before detection of hepatocellular carcinoma. *Clin Gastroenterol Hepatol* 2021;19:162-

- 170.
3. Kudo M, Galle PR, Brandi G, Kang YK, Yen CJ, Finn RS, Llovet JM, Assenat E, Merle P, Chan SL, Palmer DH, Ikeda M, Yamashita T, Vogel A, Huang YH, Abada PB, Yoshikawa R, Shinozaki K, Wang C, Widau RC, Zhu AX: Effect of ramucirumab or best supportive care on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2. *JHEP Reports* 2021;3:100215.(<https://doi.org/10.1016/j.jhepr.2020.100215>).
 4. Ikeda S, Kudo M, Izumi N, Kobayashi M, Azuma M, Meier G, Pan J, Ishii M, Kaneko S: Cost-effectiveness of lenvatinib in the treatment of patients with unresectable hepatocellular carcinomas in Japan: An analysis using data from Japanese patients in the REFLECT trial. *Value Health Reg Issues* 2021;24:82-89.
 5. Chen M, Cao J, Hu J, Topatana W, Li S, Juengpanich S, Lin J, Tong C, Shen J, Zhang B, Wu J, Pocha C, Kudo M, Amedei A, Trevisani F, Sung PS, Zaydfudim VM, Kanda T, Cai X: Clinical-radiomic analysis for pretreatment prediction of objective response to first transarterial chemoembolization in hepatocellular carcinoma. *Liver Cancer* 2021;10:38-51.
 6. Kudo M: Impact of multi-drug sequential therapy on survival in patients with unresectable hepatocellular carcinoma. *Liver Cancer* 2021;10:1-9.
 7. Kudo M, Tsuchiya K, Kato N, Hagihara A, Numata K, Aikata H, Inaba Y, Kondo S, Motomura K, Furuse J, Ikeda M, Morimoto M, Achira M, Kuroda S, Kimura A: Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: A Phase II multicenter study. *J Gastroenterol* 2021;56:181-190.
 8. Reig M, Galle PR, Kudo M, Finn R, Llovet JM, Metti AL, Schelman WR, Liang K, Wang C, Widau RC, Abada P, Zhu AX: Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab. *Liver Int* 2021;41:598-60.
 9. Kudo M, Izumi N, Kokudo N, Sakamoto M, Shiina S, Takayama T, Tateishi R, Nakashima O, Murakami T, Matsuyama Y, Takahashi A, Miyata H, Kubo S: Report of the 21st nationwide follow-up survey of primary liver cancer in Japan (2010–2011). *Hepatol Res* 2021;51:355-405.
 10. Aoki T, Kubota K, Kubo S, Eguchi S, Izumi N, Kokudo N, Sakamoto M, Shiina S, Takayama T, Nakashima O, Matsuyama Y, Murakami T, Kudo M: Analysis of patient outcome after non-curative resection for hepatocellular carcinoma using nationwide survey data in Japan. *World J Surg* 2021;45:607-614.
 11. Minami Y, Minami T, Ueshima K, Yagyu Y, Tsurusaki M, Okada T, Hori M, Kudo M, Murakami T: Three-dimensional radiological assessment of ablative margins in hepatocellular carcinoma: Pilot study of overlay fused CT/MRI imaging with automatic registration. *Cancers* 2021;13:1460.
 12. Llovet JM, Villanueva A, Marrero JA, Schwartz M, Meyer T, Galle P, Lencioni R, Greten TF, Kudo M, Mandrekar SJ, Zhu AX, Finn RS, Roberts LR, for Panel of AASLD experts on Trial Design in HCC: Trial design and endpoints in hepatocellular carcinoma: AASLD consensus conference. *Hepatology* 2021;73:158-191.
 13. Zhu AX, Finn RS, Kang YK, Yen CJ, Galle PR, Llovet JM, Assenat E, Brandi G, Motomura K, Ohno I, Daniele B, Vogel A, Yamashita T, Hsu CH, Gerken G, Bilbruck J, Hsu Y, Liang K,

- Widau RC, Wang C, Abada P, Kudo M: Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab. *Brit J Cancer* 2021;124:1388-1397.
14. Minami Y, Kudo M: Image guidance in ablation for hepatocellular carcinoma: Contrast-enhanced ultrasound and fusion imaging. *Front Oncol* 2021;11:593636.
 15. Ryoo BY, Merle P, Kulkarni AS, Cheng AL, Bouattour M, Lim HY, Breder V, Edeline J, Chao Y, Ogasawara S, Yau T, Garrido M, Chan SL, Daniele B, Norquist JM, Chen E, Siegel AB, Zhu AX, Finn RS, Kudo M: Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240. *Cancer* 2021;127:865-874.
 16. Zhang T, Merle P, Wang H, Zhao H, Kudo M: Combination therapy for advanced hepatocellular carcinoma: do we see the light at the end of the tunnel? *Hepatobiliary Surg Nutr* 2021;10:180-192.
 17. Hagiwara S, Watanabe T, Kudo M, Minaga K, Komeda Y, Kamata K, Kimura M, Hayashi H, Nakagawa K, Ueshima K, Minami Y, Aoki T, Takita M, Morita M, Chishina H, Ida H, Park AM, Nishida N: Clinicopathological analysis of hepatic immune-related adverse events in comparison with autoimmune hepatitis and graft-versus host disease. *Sci Rep* 2021;11:9242.
 18. Kudo M: Combination immunotherapy with anti-VEGF/TKI for hepatocellular carcinoma: Present and future perspective. *Hepatobiliary Surg Nutr* 2021;10:241-245.
 19. Hajiev S, Allara E, Motedayen-Aval L, Arizumi T, Bettinger D, Pirisi M, Rimassa L, Pressiani T, Personeni N, Giordano L, Kudo M, Thimme R, Park JW, Taddei TH, Kaplan DE, Ramaswami R, Pinato DJ, Sharma R: Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study. *Brit J Cancer* 2021;124:407-413.
 20. Hiraoka A, Kumada T, Tada T, Kariyama K, Tani J, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Kawata K, Yasuda S, Toyoda H, Ohama H, Nouse K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Michitaka K, Hiasa Y, Kudo M, On behalf of the Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan): What can be done to solve the unmet clinical need of hepatocellular carcinoma patients following lenvatinib failure? *Liver Cancer* 2021;10:115-125.
 21. Hajiev S, Allara E, Motedayen-Aval L, Arizumi T, Bettinger D, Pirisi M, Rimassa L, Pressiani T, Personeni N, Giordano L, Kudo M, Thimme R, Park JW, Taddei TH, Kaplan DE, Ramaswami R, Pinato DJ, Sharma R: Correction: Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study. *Brit J Cancer* 2021;124:1611.
 22. Kudo M: Sequential therapy for hepatocellular carcinoma after failure of atezolizumab plus bevacizumab combination therapy. *Liver Cancer* 2021;10:85-93.
 23. Okusaka T, Ikeda K, Kudo M, Finn RS, Qin S, Han KH, Cheng AL, Piscaglia F, Kobayashi M, Sung M, Chen M, Wyrwicz L, Yoon JH, Ren Z, Mody K, Dutcus C, Tamai T, Ren M, Hayato S, Kumada H: Safety and efficacy of lenvatinib by starting dose based on body weight in

- patients with unresectable hepatocellular carcinoma in REFLECT. *J Gastroenterol* 2021;56:570-580.
24. Kudo M, Ikeda M, Galle P, Yamashita T, Finn RS, Liang K, Wang C, Sakaguchi S, Abada P, Widau RC, Zhu AX: Ramucirumab in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: outcomes by treatment-emergent ascites. *Hepatol Res* 2021;51:715-721.
 25. Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Ohama H, Nouse K, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y, Kudo M, On behalf of the Real-life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan): Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience. *Cancer Rep* 2021;5(2):e1464.
 26. Galle PR, Finn RS, Qin S, Ikeda M, Zhu AX, Kim TY, Kudo M, Breder V, Merle P, Kaseb A, Li D, Mulla S, Verret W, Xu DZ, Hernandez S, Ding B, Liu J, Huang C, Lim HY, Cheng AL, Ducreux M: Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomized, phase 3 trial. *Lancet Oncol* 2021;22:991-1001.
 27. Pfister D, Núñez NG, Pinyol R, Govaere O, Pinter M, Szydłowska M, Gupta R, Qiu M, Deczkowska A, Weiner A, Müller F, Youssuf S, Sinha A, Friebel E, Engleitner T, Lenggenhager D, Heide D, Moncsek A, Stirm K, Kosla J, Prokosch S, Rothermel U, Dudek M, Kotsiliti E, O'Connor T, Leone V, Inverso D, Jansen J, Singh I, Yabal M, Castet F, Montironi C, Haber PK, Torrecilla S, Eichwald V, Jugold M, Ollinger R, Matter M, Terracciano L, Tiniakos D, Bedossa P, Cockell S, Younes R, Vacca M, Marra F, Schattenberg JM, Allison M, Bugianesi E, Ratzu V, Rimassa L, Daly AK, Scheiner B, Romej K, Kirstein MM, Vogel A, Peck-Radosavljevic M, Huckle F, Finkelmeier F, Waidmann A, Bueter M, Roessler F, Schmid J, Müllhaupt B, Kaeser R, Boettler T, Thimme R, Siebenhüner A, De Dosso S, Augustin HG, Schietinger A, Groth C, Umansky V, Billeter A, Müller-Stich B, Mallm JP, Mei H, Schulz A, Luedde T, Ringelhan M, Malek N, Spahn S, Bitzer M, Schirmacher P, Longerich T, Ranbari N, Dufour JF, Marron TU, Kaseb A, Kudo M, Huang YH, Teijeiro A, Djouder N, Weber A, Marche P, Pinato DJ, Decaens T, Jilkova ZM, Rad R, Mertens JC, Unger K, Meissner F, Roth S, Claassen M, Anstee QM, Amit I, Knolle P, Becher B, Llovet JM, Heikenwalder M: NASH limits anti-tumor surveillance in immunotherapy-treated HCC. *Nature* 2021;592:450-456.
 28. Kudo M, Lim HY, Cheng AL, Chao Y, Yau T, Ogasawara S, Kurosaki M, Morimoto N, Ohkawa K, Yamashita T, Lee KH, Chen E, Siegel AB, Ryoo BY: Pembrolizumab as second-line therapy for advanced hepatocellular carcinoma: A subgroup analysis of Asian Patients in the Phase 3 KEYNOTE-240 trial. *Liver Cancer* 2021;10:275-284.
 29. Kudo M, Motomura K, Wada Y, Inaba Y, Sakamoto Y, Kurosaki M, Umeyama Y, Kamei Y, Yoshimitsu J, Fujii Y, Aizawa M, Robbins PB, Furuse J: Avelumab in combination with axitinib as first-line treatment in patients with advanced hepatocellular carcinoma: results

- from the phase 1b VEGF Liver 100 trial. *Liver Cancer* 2021;10:249-259.
30. Kudo M, Kawamura Y, Hasegawa K, Tateishi R, Kariyama K, Shiina S, Toyoda H, Imai Y, Hiraoka A, Ikeda M, Izumi N, Moriguchi M, Ogasawara S, Minami Y, Ueshima K, Murakami T, Miyayama S, Nakashima O, Yano H, Sakamoto M, Hatano E, Shimada M, Kokudo N, Mochida S, Takehara T, on behalf of the HCC Expert Panel of the Japan Society of Hepatology: Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2020 update. *Liver Cancer* 2021;10:181-223.
 31. Kudo M: Surveillance, diagnosis, treatment outcomes of hepatocellular carcinoma in Japan: 2021 update. *Liver Cancer* 2021;10:167-180.
 32. Vogel A, Qin S, Kudo M, Su Y, Hudgens S, Yamashita T, Yoon JH, Fartoux L, Simon K, López C, Sung M, Mody K, Otsuka T, Tamai T, Bennett L, Meier G, Breder V: Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial. *Lancet Gastroenterol Hepatol* 2021;6:649-658.
 33. Hagiwara S, Nishida N, Ueshima K, Yoshida A, Minami Y, Kudo M: Comparison of efficacy and safety of the treatment of entecavir and switching entecavir to tenofovir alafenamide fumarate in chronic hepatitis B: Long term effects of the prospective study. *Hepatol Res* 2021;51:767-774.
 34. Kudo M: Impaired response to immunotherapy in non-alcoholic steatohepatitis-related hepatocellular carcinoma? *Liver Cancer* 2021;10:289-295.
 35. Morita M, Nishida N, Sakai K, Aoki T, Chishina H, Takita M, Ida H, Hagiwara S, Minami Y, Ueshima K, Nishio K, Kobayashi Y, Kakimi K, Kudo M: Immunological microenvironment predicts the survival of the patients with hepatocellular carcinoma treated with anti-PD-1 antibody. *Liver Cancer* 2021;10:380-393.
 36. Kudo M: Lack of response to immunotherapy in non-alcoholic steatohepatitis related hepatocellular carcinoma. *Hepatobil Surg Nutr* 2021;10:522-525.
 37. Kaibori M, Yoshii K, Kashiwabara K, Kokudo T, Hasegawa K, Izumi N, Murakami T, Kudo M, Shiina S, Sakamoto M, Nakashima O, Matsuyama Y, Eguchi S, Yamashita T, Takayama T, Kokudo N, Kubo S: Impact of hepatitis C virus on survival in patients undergoing resection of intrahepatic cholangiocarcinoma: report of a Japanese nationwide survey. *Hepatol Res* 2021;51:890-901.
 38. Hiraoka A, Kumada T, Hatanaka T, Tada T, Kariyama K, Tani J, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Kawata K, Yasuda S, Toyoda H, Ohma H, Nouse K, Tsutsui A, Nagano T, Itokawa N, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Michitaka K, Hiasa Y, Ogawa C, Tamai T, Kakizaki S, Nagashima T, Ueno T, Tojima H, Takizawa D, Naganuma A, Okubo T, Kudo M: Therapeutic efficacy of lenvatinib as third line treatment following regorafenib for unresectable hepatocellular carcinoma progression. *Hepatol Res* 2021;51:880-889.
 39. Hiraoka A, Kumada T, Tada T, Tani J, Kariyama K, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Kawata K, Yasuda S, Toyoda H, Aoki T, Anaka T, Ohama H, Nouse K, Tsutsui A,

- Nagano T, Itokawa N, Arai T, Okubo T, Imai M, Koizumi Y, Nakamura S, Joko K, Hiasa Y, Kudo M, the Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group: Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: Multi-center retrospective study. *Sci Rep* 2021;11:16663. doi.org/10.1038/s41598-021-96089-x
40. Kudo M, Matilla A, Santoro A, Melero I, Gracián AC, Acosta-Rivera M, Choo SP, El-Khoueiry AB, Kuromatsu R, El-Rayes B, Numata K, Itoh Y, Di Costanzo F, Crysler O, Reig M, Shen Y, Neely J, Tschaike M, Wisniewski T, Sangro B: CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. *J Hepatol* 2021;75:600-609.
 41. Minami Y, Morita M, Chishina H, Aoki T, Takita M, Hagiwara S, Ida H, Ueshima K, Nishida N, Kudo M: Can the entire ablative hyperechoic zone be regarded as a necrotic lesion after radiofrequency ablation of the liver? *Ultrasound Med Biol* 2021;47:2930-2935.
 42. Finn RS, Kudo M, Cheng AL, Wyrwicz L, Ngan RKC, Blanc JF, Baron AD, Vogel A, Ikeda M, Piscaglia F, Han KH, Qin S, Minoshima Y, Kanekiyo M, Ren M, Dairiki R, Tamai T, Dutcus CE, Ikezawa H, Funahashi Y, Evans TRJ: Pharmacodynamic biomarkers predictive of survival benefit with lenvatinib in unresectable hepatocellular carcinoma: From the Phase 3 REFLECT study. *Clin Cancer Res* 2021;27:4848-4858.
 43. Kelley RK, Sangro B, Harris W, Ikeda M, Okusaka T, Kang YK, Qin S, David WM Tai, Lim HY, Yau T, Yong WP, Cheng AL, Gasbarrini A, Damian S, Bruix J, Borad M, Bendell J, Kim TY, Standifer N, He P, Parmd MM, Negro A, Kudo M, Abou-Alfa GK: Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: Randomized expansion of a Phase I/II study. *J Clin Oncol* 2021;39:2991-3001.
 44. Vogel A, Merle P, Verslype C, Finn RS, Zhu AX, Cheng AL, Chan SL, Yau T, Ryou BY, Knox J, Daniele B, Qin S, Wei Z, Miteva Y, Malhotra U, Siegel AB, Kudo M: ALBI score and outcomes in patients with hepatocellular carcinoma: post hoc analysis of the randomized controlled trial KEYNOTE-240. *Ther Adv Med Oncol* 2021;13:17588359211039928. doi:10.1177/17588359211039928.
 45. Gandhi M, Ling WH, Chen CH, Lee JH, Kudo M, Chanwat R, Strasser SS, Xu Z, Lai SH, Chow PK: Impact of COVID-19 on hepatocellular carcinoma management: A multicountry and region study. *J Hepatocell Carcino* 2021;8:1159-1167.
 46. Kudo M: Adjuvant immunotherapy after curative treatment for hepatocellular carcinoma. *Liver Cancer* 2021;10:399-403.
 47. Vogel A, Frenette C, Sung M, Daniele B, Baron A, Chan SL, Blanc JF, Tamai T, Ren M, Lim HJ, Palmer DH, Takami Y, Kudo M: Baseline liver function and subsequent outcomes in the phase 3 REFLECT study of patients with unresectable hepatocellular carcinoma. *Liver Cancer* 2021;10:510-521.
 48. Hagiwara S, Nishida N, Kudo M: Improved tumor response to lenvatinib re-treatment after failure of immune checkpoint inhibitors in a patient with advanced hepatocellular carcinoma. *Liver Cancer* 2021;10:535-538.
 49. Kudo M, Finn R, Morimoto M, Rau KM, Ikeda M, Yen CJ, Galle PR, Llovet J, Daniele B, Lim

- HY, McIlwain DW, Yoshikawa R, Nakamura K, Liang K, Wang C, Abada P, Widau RC, Zhu AX: Ramucirumab for patients with intermediate-stage hepatocellular carcinoma and elevated alpha-fetoprotein: pooled results from two phase 3 studies (REACH and REACH-2). *Liver Cancer* 2021;10:451-460.
50. Yamashita Y, Shimokawa T, Ashida R, Dietrich CF, D'Onofrio M, Hirooka Y, Kudo M, Mori H, Sofuni A, Kitano M: Value of low-mechanical-index contrast-enhanced transabdominal ultrasound for diagnosis of pancreatic cancer: A meta-analysis. *Ultrasound Med Biol* 2021;47:3315-3322.
 51. Galle PR, Kudo M, Llovet JM, Finn RS, Karwal M, Pezet D, Kim TY, Yang TS, Lonardi S, Tomasek J, Phelip JM, Toucheffeu Y, Koh SJ, Stirnimann G, Liang K, Ogburn KD, Wang C, Abada P, Widau RC, Zhu AX: Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease etiology. *Liver Int* 2021;41:2759-2767.
 52. Kudo M: Changing the treatment paradigm for hepatocellular carcinoma using atezolizumab plus bevacizumab combination therapy. *Cancers* 2021;13:5475. doi:10.3390/cancers13215475.
 53. Hagiwara S, Nishida N, Ueshima K, Minami Y, Komeda Y, Aoki T, Takita M, Morita M, Chishina H, Yoshida A, Ida H, Kudo M: Accumulation of genetic and epigenetic alterations in the background liver and emergence of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease. *Cells* 2021;10:3257. doi: 10.3390/cells10113257
 54. Sakai K, Sakurai T, De Velasco MA, Nagai T, Chikugo T, Ueshima K, Kura Y, Takahama T, Hayashi H, Nakagawa K, Kudo M, Nishio K: Intestinal microbiota and gene expression reveal similarity and dissimilarity between Immune-mediated colitis and ulcerative colitis. *Front Oncol* 2021;11:763468. doi:10.3389/fonc.2021.763468
 55. Kudo M: A novel treatment strategy for patients with Intermediate-stage HCC who are not suitable for TACE: Upfront systemic therapy followed by curative conversion. *Liver Cancer* 2021;10:539-544.
 56. Fessas P, Naeem M, Pinter M, Marron TU, Szafron D, Balcar L, Scheiner B, Saeed A, Jun T, Dharmapuri S, Gampa A, Wang Y, Khan U, Muzaffar M, Navaid M, Lee PC, Bulumulle A, Yu B, Paul S, Nimkar N, Bettinger D, Hildebrand H, Yehia M, Pressiani T, Personeni N, Nishida N, Kudo M, Kaseb A, Huang YH, Ang C, Pillai A, Rimassa L, Naqash AR, Sharon E, Cortellijni A, Pinato DJ: Early antibiotic exposure is not detrimental to therapeutic effect from immunotherapy in hepatocellular carcinoma. *Liver Cancer* 2021;10:583-592.
 57. Aoki T, Nishida N, Ueshima K, Morita M, Chishina H, Takita M, Hagiwara S, Ida H, Minami Y, Yamada A, Sofue K, Tsurusaki M, Kudo M: Higher enhancement intrahepatic nodules on the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI as a poor responsive marker of anti-PD-1 / PD-L1 monotherapy for unresectable hepatocellular carcinoma. *Liver Cancer* 2021;10:615-628.
 58. Hiraoka A, Kumada T, Kariyama K, Tada T, Tani J, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Kawata K, Yasuda S, Toyoda H, Ohama H, Nouse K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Arai T, Imai M, Koizumi Y, Nakamura S, Michitaka K, Hiasa Y, Kudo M,

- on behalf of the Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan): Clinical importance of muscle volume in lenvatinib for hepatocellular carcinoma: analysis adjusted with inverse probability weighting. *J Gastroenterol Hepatol* 2021;36:1812-1819.
59. Koh DM, Ba-Ssalamah A, Brancatelli G, Fananapazir G, Fiel MI, Goshima S, Ju SH, Kartalis N, Kudo M, Lee JM, Murakami T, Seidensticker M, SirlinCB, Tan CH, Wang J, Yoon JH, Zeng M, Zhou J, Taouli B: Consensus report from the 9th International Forum for Liver Magnetic Resonance Imaging: applications of gadoxetic acid-enhanced imaging. *Eur Radiol* 2021;31:5615-5628.
 60. Kawaguchi Y, Hasegawa K, Hagiwara Y, De Bellis M, Famularo S, Panettieri E, Matsuyama Y, Tateishi R, Ichikawa T, Kokudo T, Izumi N, Kubo S, Sakamoto M, Shiina S, Takayama T, Nakashima O, Murakami T, Vauthey JN, Giulante F, De Carlis L, Romano F, Ruzzenente A, Guglielmi A, Kudo M, Kokudo N: Effect of diameter and number of hepatocellular carcinomas on survival after resection, trans-arterial chemoembolization, and ablation. *Am J Gastroenterol* 2021;116:1698-1708.
 61. Muhammed A, Fulgenzi CAM, Pinter M, Balcar L, Marron TU, Jun T, Dharmapuri S, Ang C, Saeed A, Hildebrand H, Navaid M, Naqash AR, Gampa A, Vincenzi B, Silletta M, Pillai A, Wang Y, Muzaffar M, Khan U, Huang YH, Bettinger D, Abugabal YI, Kaseb A, Pressiani T, Personeni N, Rimassa L, Nishida N, Tommaso LD, Kudo M, Vogel A, Mauri FA, Cortellini A, Sharma R, D'Alessio A, Pinato DJ: The systemic inflammatory response identifies patients with adverse clinical outcome from immunotherapy in hepatocellular carcinoma. *Cancers* 2021;14:186. doi:10.3390/cancers14010186.
- 2) 学会発表
1. Fessas P, Naeem M, Marron TU, Szafron D, Sharon E, Saeed A, Jun T, Dharmapuri S, Naqash AR, Peeraphatdit T, Gampa A, Wang Y, Khan U, Muzaffar M, Navaid M, Lee CJ, Lee PC, Bulumulle A, Yu B, Paul S, Nimkar N, Bettinger D, Hildebrand H, Abugabal YI, Pressiani T, Personeni N, Nishida N, Kudo M, Kaseb A, Huang YH, Ang C, Pillai A, Rimassa L, Pinato DJ: Early antibiotic exposure delays disease progression following immune checkpoint inhibitor therapy for hepatocellular carcinoma: evidence from an observational study. American Association for Cancer Research Annual Meeting (AACR 2021), April 10-15, 2021. (Virtual Meeting).
 2. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, Kudo M, Lim HY, Breder VV, Merle P, Kaseb AO, Li D, Feng YH, Verret W, Nicholas A, Li L, Ma N, Zhu AX, Cheng AL: IMbrave150: updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC). American Association for Cancer Research Annual Meeting (AACR 2021), April 10-15, 2021. (Virtual Meeting)
 3. Kudo M, Ueshima K, Nakahira S, Nishida N, Ida H, Minami Y, Kobayashi S, Umeda M, Tsurusaki M, Chiba Y, Yoshimura K, Sakai K, Nishio K: Adjuvant nivolumab for hepatocellular carcinoma (HCC) after surgical resection (SR) or radiofrequency ablation (RFA) (NIVOLVE): A phase 2 prospective

- multicenter single arm trial and exploratory biomarker analysis. American Society of Clinical Oncology (ASCO 2021), June 4-8, 2021 (Online).
4. Kudo M, Hasegawa K, Kawaguchi Y, Takayama T, Izumi N, Yamanaka N, Shimada M, Inomata M, Kaneko S, Baba H, Koike K, Omata M, Makuuchi M, Matsuyama Y, Kokudo N: A multicenter randomized controlled trial to evaluate the efficacy of surgery versus radiofrequency ablation for small hepatocellular carcinoma (SURF trial): analysis of overall survival. American Society of Clinical Oncology (ASCO 2021), June 4-8, 2021 (Online).
 5. Zhu AX, Llovet JM, Kobayashi M, Ikeda M, Gerolami R, Pracht M, Sung MW, Baron AD, Kudo M, Meyer T, Okusaka T, Kumada H, Kaneko S, Hoshi T, Saito K, Li SD, Funahashi Y, Minoshima Y, Dubrovsky L, Finn RS: Exploratory circulating biomarker analyses: lenvatinib plus pembrolizumab in a phase 1b trial in unresectable hepatocellular carcinoma (uHCC). American Society of Clinical Oncology (ASCO 2021), June 4-8, 2021 (Online).
 6. Laethem JLV, Borbath I, Karwal M, Verslype C, Vlierberghe HV, Kardosh A, Zagonel V, Stal P, Sarker D, Palmer DH, Vogel A, Edeline S, Cattani S, Kudo M, Cheng AL, Ogasawara S, Siegel AB, Chisamore MJ, Wang A, Zhu AX: Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): phase 2 KEYNOTE-224 study. American Society of Clinical Oncology (ASCO 2021), June 4-8, 2021 (Online).
 7. Llovet JM, Singal AG, Villanueva A, Finn RS, Kudo M, Galle PR, Wang C, Widau RC, Gugel EG, Zhu AX: Prognostic and predictive factors in patients treated with ramucirumab (RAM) with advanced hepatocellular carcinoma (aHCC) and elevated alpha-fetoprotein (AFP): results from two Phase III trials. American Society of Clinical Oncology (ASCO 2021), June 4-8, 2021 (Online).
 8. Matilla A, Sangro B, El-Khoueiry AB, Santoro A, Melero I, Gracián AC, Acosta-Rivera M, Choo SP, Kuromatsu R, El-Rayes B, Numata K, Itoh Y, De Costanzo F, Crysler O, Reig M, Shen Y, Yao J, Neely J, Tschaike M, Kudo M: CheckMate 040: long-term efficacy and safety of nivolumab in patients with Child-Pugh B advanced hepatocellular carcinoma: associations between baseline biomarker analyses and outcomes. The International Liver Congress 2021 (EASL 2021), June 23-26, 2021.
 9. Peck-Radosavljevic M, Lencionia R, Ozgurdal K, Kudo M: Sorafenib in extended patient populations in real-world clinical practice: Baseline characteristics from OPTIMIS and GIDEON. 23rd World Congress on Gastrointestinal Cancer (WCGI 2021), June 30-July 3, 2021.
 10. Kudo M: Relatlimab + nivolumab in patients with advanced hepatocellular carcinoma who are naive to immuno-oncology therapy but progressed on tyrosine kinase inhibitors, a phase 2, randomized, open-label study: RELATIVITY-073. ESMO World Congress on Gastrointestinal Cancer 2021 (ESMO-GI 2021), June 30-July 3, 2021 (Virtual).
 11. Li D, Cheng AL, Lim HY, Llovet JM, Zhu Y, Hatogai K, Siegel AB, Kudo M: Pembrolizumab/Quavonlimab coformulation in combination with lenvatinib in advanced hepatocellular carcinoma: Phase 2 trial in progress. ESMO World Congress on Gastrointestinal Cancer 2021 (ESMO-GI 2021), June 30-July 3, 2021 (Virtual).

12. Trojan J, Meyer T, Yau T, Melero I, Kudo M, Hsu C, Kim TY, Choo SP, Kang YK, Yeo W, Chopra A, Soleymani S, Yao J, Neely J, Tschaika M, Welling III TH, Sangro B, El-Khoueiry A: cNivolumab (NIVO) in sorafenib (SOR)-naive and -experienced patients with advanced hepatocellular carcinoma (aHCC): 5-year follow-up from CheckMate 040 cohorts 1 and 2. The International Liver Cancer Association (ILCA 2021), September 2-5, 2021
13. Kudo M, Finn RS, Cheng AL, Zhu AX, Ducreux M, Galle P, Gaillard VE, Nicholas A, Vogel A: IMbrave150: Albumin-bilirubin grade analyses in a phase III study of atezolizumab + bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma. The International Liver Cancer Association (ILCA 2021), September 2-5, 2021
14. Kudo M, Lencionia R, Ozgurdal K, Peck-Radosavljevic M: Sorafenib in extended patient populations in real-world clinical practice: Baseline characteristics from OPTIMIS and GIDEON. The International Liver Cancer Association (ILCA 2021), September 2-5, 2021.
15. Lim HY, Merle P, Ikeda M, Masi G, Finn RS, Frenette C, Klumpen HJ, Kim YJ, Gerolami R, Kurosaki M, Numata K, Zebger-Gong H, Fiala-Buskies S, Ozgurdal K, Kudo M, Qin S: Regorafenib in patients with unresectable hepatocellular carcinoma in routine clinical practice: Updated interim analysis of the prospective observational REFINE study. The International Liver Cancer Association (ILCA 2021), September 2-5, 2021.
16. Galle PR, Finn RS, Qin S, Ikeda M, Ducreux M, Kim TY, Lim HY, Kudo M, Breder VV, Merle P, Kaseb AO, Li D, Verret W, Shao H, Liu J, Li L, Zhu AX, Cheng AL: IMbrave150: updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC). National meeting of the German Society of Hematology & Oncology, September 13-18, 2021.
17. Ikeda M, Yamashita T, Ogasawara S, Kudo M, Inaba Y, Morimoto M, Tsuchiya K, Shimizu S, Kojima Y, Hiraoka A, Nouse K, Aikata H, Numata K, Sato T, Okusaka T, Furuse J: Multicenter Phase II trial of lenvatinib plus hepatic intra-arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma: LEOPARD. European Society for Medical Oncology (ESMO) congress, September 16-21, 2021.
18. Kudo M, Finn RS, Zhu AX, Sung MW, Baron AD, Okusaka T, Kobayashi M, Kumada H, Kaneko S, Pracht M, Meyer T, Nagao S, Saito K, Mody K, Dubrovsky L, Llovet JM: A phase 1b study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma: Study 116 follow-up analysis. ESMO Immuno-Oncology Congress 2021, Geneva, Switzerland, December 8-11, 2021.
19. Kudo M, Ueshima K, Nakahira S, Nishida N, Ida H, Minami Y, Nakai T, Wada H, Kubo S, Ohkawa K, Morishita A, Nomi T, Ishida K, Kobayashi S, Umeda M, Tsurusaki M, Chiba Y, Yoshimura K, Sakai K, Nishio K: Final results of adjuvant nivolumab for hepatocellular carcinoma (HCC) after surgical resection (SR) or radiofrequency ablation (RFA) (NIVOLVE): A phase 2 prospective multicenter single-arm trial and exploratory biomarker analysis. Gastrointestinal Cancers Symposium (ASCO-GI 2022), San Francisco, USA, January 20-22, 2022.

20. Kudo M, Guo Y, Hua Y, Zhao M, Xing W, Zhang Y, Liu R, Ren Z, Gu S, Lin Z, Lv W, Wang Y, Dong J: TALENTACE: A phase III, open-label, randomized study of on-demand transarterial chemoembolization combined with atezolizumab + bevacizumab or on-demand transarterial chemoembolization alone in patients with untreated hepatocellular carcinoma. Gastrointestinal Cancers Symposium (ASCO-GI 2022), San Francisco, USA, January 20-22, 2022.
21. Ueshima K, Ishikawa T, Saeki I, Morimoto N, Aikata H, Tanabe N, Inaba Y, Wada Y, Kondo Y, Tsuda M, Nakao K, Ikeda M, Moriguchi M, Ito T, Kobayashi M, Koga H, Hino K, Suzuki Y, Yoshimura K, Kudo M: Transcatheter arterial chemoembolization therapy in combination strategy with lenvatinib in patients with unresectable hepatocellular carcinoma (TACTICS-L) in Japan: Final analysis. Gastrointestinal Cancers Symposium (ASCO-GI 2022), San Francisco, USA, January 20-22, 2022.
22. El-Khoueiry AB, Llovet J, Vogel A, Madoff DC, Finn RS, Ogasawara S, Ren Z, Mody K, Li JJ, Siegel AB, Dubrovsky L, Kudo M: LEAP-012 trial in progress: Transarterial chemoembolization (TACE) with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma (HCC) not amenable to curative treatment. Gastrointestinal Cancers Symposium (ASCO-GI 2022), San Francisco, USA, January 20-22, 2022.
23. Abou-Alfa GK, Chan SL, Kudo M, Lau G, Kelley RK, Furuse J, Sukeepaisarnjaroen W, Kang YK, Tu DV, De Toni EN, Rimassa L, Breder VV, Vasilyev A, Heurgue A, Tam V, Mody K, Thungappa SC, He P, Negro A, Sangro B: Phase 3 randomized, open-label, multicenter study of tremelimumab and durvalumab as first-line therapy in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA. Gastrointestinal Cancers Symposium (ASCO-GI 2022), San Francisco, USA, January 20-22, 2022.
24. Finn RS, Kudo M, Klumpen HJ, Lim HY, Merle P, Ikeda M, Masi G, Frenette CT, Kim YJ, Gerolami R, Kurosaki M, Numata K, Pisarenko J, Ozgurdal K, Qin S: Regorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in routine clinical practice: Exploratory analysis of overall survival (OS) in the prospective, observational REFINE study. Gastrointestinal Cancers Symposium (ASCO-GI 2022), San Francisco, USA, January 20-22, 2022.
25. Lim HY, Heo J, Kim TY, Meng W, Tai D, Kang YK, Lau G, Kudo M, Tak WY, Watras M, Ali SK, Negro A, Abou-Alfa GK, Kelley RK: Safety and efficacy of durvalumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from the phase 2 study 22 (NCT02519348). Gastrointestinal Cancers Symposium (ASCO-GI 2022), San Francisco, USA, January 20-22, 2022.
26. Finn RS, Kudo M, Kim YJ, Lim HY, Merle P, Ikeda M, Masi G, Frenette CT, Klumpen HJ, Gerolami R, Kurosaki M, Numata K, Pisarenko J, Khan J, Ozgurdal K, Qin S: Regorafenib in patients with unresectable hepatocellular carcinoma in routine clinical practice: Exploratory analysis of safety and overall survival in the prospective, observational REFINE study. EASL Liver Cancer Summit 2022, Estoril, Portugal, February 3-5, 2022.
27. Talbot T, D'Alessio A, Pinter M, Balcar L, Scheiner B, Marron TU, Jun T, Dharmapuri S, Ang C, Saeed A, Hildebrand H, Muzaffar M,

Fulgenzi CAM, Amara S, Naqash AR, Gampa A, Pillai A, Wang Y, Khan U, Lee PC, Huang YH, Bengsch B, Bettinger D, Abugabal YI, Kaseb A, Pressiani T, Personeni N, Rimassa L, Nishida N, Kudo M, Weinmann A, Galle PR, Muhammed A, Cortellini A, Vogel A, Pinato DJ: Progression patterns and therapeutic sequencing following immune checkpoint inhibition for HCC: an observational study. EASL Liver Cancer Summit 2022, Estoril, Portugal, February 3-5, 2022.

H. 知的財産権の出願・登録状況（予定を含む）

- 1) 特許取得：なし
- 2) 実用新案登録：なし
- 3) その他：なし